BR112012000942B8 - processos para a produção de poliovírus, e para produzir uma vacina contra pólio - Google Patents

processos para a produção de poliovírus, e para produzir uma vacina contra pólio

Info

Publication number
BR112012000942B8
BR112012000942B8 BR112012000942A BR112012000942A BR112012000942B8 BR 112012000942 B8 BR112012000942 B8 BR 112012000942B8 BR 112012000942 A BR112012000942 A BR 112012000942A BR 112012000942 A BR112012000942 A BR 112012000942A BR 112012000942 B8 BR112012000942 B8 BR 112012000942B8
Authority
BR
Brazil
Prior art keywords
producing
poliovirus
processes
cells
polio vaccine
Prior art date
Application number
BR112012000942A
Other languages
English (en)
Other versions
BR112012000942B1 (pt
BR112012000942A2 (pt
Inventor
Alfred Lewis John
Original Assignee
Crucell Holland Bv
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv, Janssen Vaccines & Prevention Bv filed Critical Crucell Holland Bv
Publication of BR112012000942A2 publication Critical patent/BR112012000942A2/pt
Publication of BR112012000942B1 publication Critical patent/BR112012000942B1/pt
Publication of BR112012000942B8 publication Critical patent/BR112012000942B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32651—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

processos para a produção de poliovírus, e para produzir uma vacina contra pólio. a invenção fornece um processo para a produção de poliovírus, que compreende as etapas de: a) fornecer uma cultura de células em suspensão livre de soro, que são células per.c6, b) infectar as ditas células com poliovírus, em uma densidade celular entre 2 x 106 células/ml e150 x 106 células/ml e c) cultivar poliovírus em um período entre 12 e 48 horas após a infecção.
BR112012000942A 2009-07-16 2010-07-08 processos para a produção de poliovírus, e para produzir uma vacina contra pólio BR112012000942B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27103809P 2009-07-16 2009-07-16
US61/271,038 2009-07-16
EP09165620 2009-07-16
EP09165620.7 2009-07-16
PCT/EP2010/059796 WO2011006823A1 (en) 2009-07-16 2010-07-08 Production of polio virus at high titers for vaccine production

Publications (3)

Publication Number Publication Date
BR112012000942A2 BR112012000942A2 (pt) 2016-03-15
BR112012000942B1 BR112012000942B1 (pt) 2020-10-27
BR112012000942B8 true BR112012000942B8 (pt) 2021-05-25

Family

ID=41412431

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012000942A BR112012000942B8 (pt) 2009-07-16 2010-07-08 processos para a produção de poliovírus, e para produzir uma vacina contra pólio

Country Status (33)

Country Link
US (4) US8546123B2 (pt)
EP (1) EP2454364B1 (pt)
JP (1) JP5845178B2 (pt)
KR (1) KR101548790B1 (pt)
CN (1) CN102482647B (pt)
AP (1) AP3140A (pt)
AR (1) AR077314A1 (pt)
AU (1) AU2010272685B2 (pt)
BR (1) BR112012000942B8 (pt)
CA (1) CA2763091C (pt)
CO (1) CO6491042A2 (pt)
CU (1) CU20120006A7 (pt)
DK (1) DK2454364T3 (pt)
EA (1) EA020563B1 (pt)
ES (1) ES2484093T3 (pt)
HK (1) HK1164922A1 (pt)
HR (1) HRP20140597T1 (pt)
IL (1) IL217465A (pt)
MA (1) MA33429B1 (pt)
MX (1) MX2011012648A (pt)
MY (1) MY183385A (pt)
NZ (1) NZ596880A (pt)
PE (1) PE20120571A1 (pt)
PL (1) PL2454364T3 (pt)
PT (1) PT2454364E (pt)
RS (1) RS53377B (pt)
SG (1) SG177655A1 (pt)
SI (1) SI2454364T1 (pt)
SM (1) SMT201400079B (pt)
TN (1) TN2011000628A1 (pt)
TW (1) TWI477606B (pt)
WO (1) WO2011006823A1 (pt)
ZA (1) ZA201108271B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647985C (en) 2006-03-31 2014-12-30 Warf-Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
SG177655A1 (en) * 2009-07-16 2012-02-28 Crucell Holland Bv Production of polio virus at high titers for vaccine production
EP2493912B1 (en) 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US10137188B2 (en) * 2013-02-05 2018-11-27 University Of Georgia Research Foundation, Inc. Cell lines for virus production and methods of use
EA030749B1 (ru) 2013-03-08 2018-09-28 Янссен Вэксинс Энд Превеншн Б.В. Бесклеточная противококлюшная вакцина
CN105121634B (zh) 2013-03-13 2019-07-26 易木农麦克斯有限公司 具有提高的病毒生产能力的细胞系及其生产方法
KR20140112255A (ko) 2013-03-13 2014-09-23 고려대학교 산학협력단 바이러스 생산능이 증가된 세포주 및 그 제조방법
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
PL3010537T3 (pl) 2013-06-17 2019-03-29 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport Sposoby zapobiegania agregacji komponentów wirusowych
WO2015009743A1 (en) 2013-07-15 2015-01-22 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs
US20160053281A1 (en) * 2013-08-15 2016-02-25 The University Court Of The University Of Edinburgh Enhanced Expression Of RNA Vectors
JP6783143B2 (ja) 2014-03-25 2020-11-11 テルモ ビーシーティー、インコーポレーテッド 培地の受動的補充
CA2951351C (en) 2014-06-17 2023-03-14 Janssen Vaccines & Prevention B.V. Cold-adapted-viral-attenuation (cava) and novel attenuated poliovirus strains
US10526393B2 (en) 2014-06-18 2020-01-07 Immunomax Co., Ltd. Method for promoting virus infection and increasing virus production, by using cell line having lost BST2 gene functions
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US10294460B2 (en) 2014-07-24 2019-05-21 Janssen Vaccines & Prevention B.V. Process for the purification of poliovirus from cell cultures
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. CELL EXPANSION
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US10372100B2 (en) * 2016-08-29 2019-08-06 Ge Healthcare Bio-Sciences Corp. Manufacturing system for biopharmaceutical products
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
CN107723279B (zh) * 2017-10-18 2020-11-10 成都远睿生物技术有限公司 一种缺陷型腺病毒AdC68-GP的培养方法
SG11202007503WA (en) * 2018-02-07 2020-09-29 Bharat Biotech Int Ltd A process for enterovirus purification and inactivation and vaccine compositions obtained thereof
US11241492B2 (en) 2019-01-23 2022-02-08 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to genes in influenza viruses
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
WO2020229581A1 (en) 2019-05-16 2020-11-19 Janssen Vaccines & Prevention B.V. Methods for inducing a safe immune response against polio virus
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525349A (en) * 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
DE69633565T3 (de) 1995-06-15 2013-01-17 Crucell Holland B.V. Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie
EP1103610A1 (en) * 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
EP1256803A1 (en) * 2001-05-07 2002-11-13 Crucell Holland B.V. Methods for the identification of antiviral compounds
WO2004037294A2 (en) * 2002-10-23 2004-05-06 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
WO2004055187A1 (en) * 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
NZ542585A (en) * 2003-05-09 2007-11-30 Crucell Holland Bv Cultures of PER.C6-immortalized cells and processes for culturing the same to increase product yields therefrom
US8206981B2 (en) 2004-03-05 2012-06-26 Dsm Ip Assets B.V. Process for cell culturing by continuous perfusion and alternating tangential flow
US20080193478A1 (en) 2004-08-27 2008-08-14 Rajesh Jain Inactivated Poliomyelitis Vaccine Derived From Sabin Strain Of Polio Virus
KR20070104881A (ko) * 2004-10-14 2007-10-29 크루셀 홀란드 비.브이. 말라리아 프라임/부스트 백신
CN100500827C (zh) * 2004-11-26 2009-06-17 中国医学科学院医学生物学研究所 用人胚肺二倍体细胞培养繁殖脊髓灰质炎病毒的方法
US20100144620A1 (en) * 2006-11-16 2010-06-10 Crucell Holland B.V. Complementation of factor xi deficeincy by factor v mutants
SG177655A1 (en) 2009-07-16 2012-02-28 Crucell Holland Bv Production of polio virus at high titers for vaccine production
KR20120070015A (ko) 2010-12-21 2012-06-29 (주)창조바이오텍 알파-피넨을 유효성분으로 포함하는 스쿠티카충 구제용 조성물

Also Published As

Publication number Publication date
AR077314A1 (es) 2011-08-17
HRP20140597T1 (hr) 2014-09-12
AP3140A (en) 2015-02-28
ES2484093T3 (es) 2014-08-11
SMT201400079B (it) 2014-09-08
MA33429B1 (fr) 2012-07-03
CN102482647A (zh) 2012-05-30
WO2011006823A1 (en) 2011-01-20
SI2454364T1 (sl) 2014-08-29
BR112012000942B1 (pt) 2020-10-27
HK1164922A1 (en) 2012-09-28
RS53377B (en) 2014-10-31
US9022240B2 (en) 2015-05-05
TW201118173A (en) 2011-06-01
US20110027317A1 (en) 2011-02-03
TWI477606B (zh) 2015-03-21
CO6491042A2 (es) 2012-07-31
AU2010272685A1 (en) 2011-12-08
KR20120033334A (ko) 2012-04-06
AP2012006075A0 (en) 2012-02-29
PE20120571A1 (es) 2012-06-06
US20140242670A1 (en) 2014-08-28
IL217465A (en) 2016-05-31
KR101548790B1 (ko) 2015-08-31
EP2454364B1 (en) 2014-04-23
CA2763091A1 (en) 2011-01-20
EP2454364A1 (en) 2012-05-23
CU20120006A7 (es) 2012-10-15
TN2011000628A1 (en) 2013-05-24
JP5845178B2 (ja) 2016-01-20
PL2454364T3 (pl) 2014-09-30
MY183385A (en) 2021-02-18
CA2763091C (en) 2019-07-23
US20130273106A1 (en) 2013-10-17
JP2012532616A (ja) 2012-12-20
US8546123B2 (en) 2013-10-01
SG177655A1 (en) 2012-02-28
ZA201108271B (en) 2012-07-25
US20130052224A1 (en) 2013-02-28
NZ596880A (en) 2013-10-25
IL217465A0 (en) 2012-02-29
EA020563B1 (ru) 2014-12-30
CN102482647B (zh) 2015-12-16
PT2454364E (pt) 2014-07-04
EA201270173A1 (ru) 2012-06-29
DK2454364T3 (da) 2014-07-21
MX2011012648A (es) 2012-01-12
BR112012000942A2 (pt) 2016-03-15
AU2010272685B2 (en) 2015-02-26

Similar Documents

Publication Publication Date Title
BR112012000942B8 (pt) processos para a produção de poliovírus, e para produzir uma vacina contra pólio
MY156588A (en) Systems using cell culture for production of isoprene
MY168208A (en) Recombinant microorganisms and uses therefor
AR066239A1 (es) Metodo para la produccion de proteinas mediante celulas cultivadas
WO2010096588A3 (en) Cell culture media containing combinations of proteins
WO2010089151A8 (en) Bioreactor for the cultivation of mammalian cells
BR112013009583A2 (pt) ácido nucleico, vetor, célula hospedeira, métodos de preparação de uma linhagem bacteriana variante de tipificação, de marcação, de geração e de controle de populações bacterianas, linhagem e célula bacteriana variante, kit, uso de um ácido nucleico, cultivo celular, produto, processo de preparação de produtos, mutantes de fago e mutante de escape de fago
EA200801221A1 (ru) Вирусные вакцины, полученные из клеток, с низкими уровнями остаточной клеточной днк
BR112013009552A2 (pt) produção de butanol a partir de monóxido de carbono por um micro-organismo recombinante
MY194500A (en) Methods and Compositions for Producing Fatty Alcohols
NZ600376A (en) Elite event ee-gm3 and methods and kits for identifying such event in biological samples
BR112012005844A2 (pt) Método para cultivar microalgas capazes de crescimento heterotrófico, método para fabricar um material, e sistema de biorreator
SG196784A1 (en) Stem cell cultures
BRPI0506369A (pt) microorganismos, e, métodos para produzir um l-aminoácido
PH12014501175A1 (en) Medium composition for rejuvenating stem cells
WO2011075686A3 (en) Methods & compositions comprising heat shock proteins
MX2021009554A (es) Produccion de virus en cultivos celulares.
BR112015005416A2 (pt) produção de ácidos orgânicos por meio de fermentação em baixo ph
PH12014502870A1 (en) Method of producing recombinant iduronate-2-sulfatase
EP3666900A3 (en) Cell-based production of nonulosonates
BR112013014082A2 (pt) "moléculas de rna, micro-rna e de ácido nucleico, composições e construtos compreendendo as mesmas, bem como métodos para melhorar a resistência 5 de uma planta à infecção, controlar a infecção e reduzir o desenvolvimento do cisto de um nematódeo, para produção de uma célula ou de uma planta possuindo resistência a nematódeo e para melhorar a produtividade".
GB2452892A (en) Process for culturing bacteria of the piscirickettsia genus
NZ708061A (en) Methods for generating genetically superior animals
WO2018183848A8 (en) Media for microorganism culture and related compositions and methods
ES2351296B8 (es) Cepas de s. cerevisiae capaces de crecer en medios con melibiosa, estaquiosa y rafinosa.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: JANSSEN VACCINES AND PREVENTION B.V (NL)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B25G Requested change of headquarter approved

Owner name: JANSSEN VACCINES AND PREVENTION B.V (NL)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/07/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF